Successful Transport of Blood Samples with Small Drones
|
By LabMedica International staff writers Posted on 17 Aug 2015 |

Image: Preparation of clinical blood samples for test-flights by small drone. (1) Left: Custom-cut foam block. (2) Right: Placement of sealed foam lock in the bio-hazard bags as well as absorbent material for potential sample containment (Photos courtesy of Johns Hopkins Medicine and PLOS One).

Image: (3) Left: Placement of first bio-hazard bag inside the second bio-hazard bag. (4) Middle-right: Placement of double-wrapped payload in the fuselage (Photo courtesy of Johns Hopkins Medicine and PLOS One).

Image: (5) Left: Covered, secured, and labeled fuselage. (6) Right: Launch with hand toss (Photo courtesy of Johns Hopkins Medicine and PLOS One).
A proof-of-concept, initial study has shown that small unmanned aerial systems (UAS) could potentially be used to transport clinical blood specimens for diagnostics without damage to the specimens.
In a first rigorous examination published about the impact of drone transport on biological samples, a team of clinical researchers and engineers, led by Timothy Kien Amukele, MD, PhD, pathologist at Johns Hopkins University School of Medicine (Baltimore, MD, USA) and director of a collaboration with Makerere University in Uganda, found that results of common, routine tests on the blood samples were not affected by up to 40 minutes of sample-travel in hobby-sized drones. This could especially aid millions of people in developing nations where most tests are currently done by dedicated laboratories that can be scores of miles from remote clinics in rural and economically impoverished areas that lack, for example, good roads.
“Biological samples can be very sensitive and fragile,” said Dr. Amukele. That sensitivity makes even the pneumatic-tube systems used by many hospitals, for example, unsuitable for transporting blood for certain purposes. Of particular concern related to sample transport in drones is the sudden acceleration that marks the launch of the vehicle and the jostling when the drone lands on its belly. “Such movements could have destroyed blood cells or prompted blood to coagulate and I thought all kinds of blood tests might be affected, but our study shows they weren’t,” he added.
For the study, total of 6 blood samples were collected from each of 56 healthy adult volunteers at Johns Hopkins Hospital. Samples were driven to a flight site an hour’s drive from the hospital on days when the temperature was moderate. There, half the samples were held stationary (non-flight); the other half were packaged for protection during the in-flight environment and to prevent leakage, then loaded into a hand-launched fixed-wing drone and flown for periods of 6–38 minutes. Owing to Federal Aviation Administration (FAA) rules, the flights were conducted in an unpopulated area, kept below 100 meters and in the line-of-sight of the certified drone pilot.
Samples were driven back from the flight-field to the Johns Hopkins Hospital Core Laboratory, where 33 of the most common chemistry, hematology, and coagulation tests were performed (tests that together account for around 80% of all such tests performed), including for sodium, glucose, and red blood cell count.
Comparing lab results of the flown vs. non-flown samples from each volunteer showed that these flights essentially had no impact, although the precision of one blood test—for total carbon dioxide (the bicarbonate test)—did differ for some samples pairs. This may be because the blood sat for up to 8 hours before being tested, but whether the out-of-range results were due to this time lag or to the drone transport is unknown. Nevertheless, there were no consistent differences in results between the flown vs. non-flown blood.
“The ideal way to test that would be to fly the blood around immediately after drawing it, but neither the FAA nor Johns Hopkins would like drones flying around the hospital,” said Dr. Amukele.
The likely next step is a pilot study in Africa where clinics are sometimes 60 or more miles away from labs. “A drone could go 100 km in 40 minutes,” said Dr. Amukele, “They’re less expensive than motorcycles, are not subject to traffic delays, and the technology already exists for the drone to be programmed to “home” to certain GPS coordinates, like a carrier pigeon.”
Drones have already been tested as carriers of medicines to clinics in remote areas, but whether and how drones will be used to carry medicines and potentially infectious patient specimens over more populated areas will depend on laws and regulations.
The study, by Amukele TK, et al, was published July 29, 2015, in the journal PLOS One.
Related Links:
Johns Hopkins University School of Medicine
In a first rigorous examination published about the impact of drone transport on biological samples, a team of clinical researchers and engineers, led by Timothy Kien Amukele, MD, PhD, pathologist at Johns Hopkins University School of Medicine (Baltimore, MD, USA) and director of a collaboration with Makerere University in Uganda, found that results of common, routine tests on the blood samples were not affected by up to 40 minutes of sample-travel in hobby-sized drones. This could especially aid millions of people in developing nations where most tests are currently done by dedicated laboratories that can be scores of miles from remote clinics in rural and economically impoverished areas that lack, for example, good roads.
“Biological samples can be very sensitive and fragile,” said Dr. Amukele. That sensitivity makes even the pneumatic-tube systems used by many hospitals, for example, unsuitable for transporting blood for certain purposes. Of particular concern related to sample transport in drones is the sudden acceleration that marks the launch of the vehicle and the jostling when the drone lands on its belly. “Such movements could have destroyed blood cells or prompted blood to coagulate and I thought all kinds of blood tests might be affected, but our study shows they weren’t,” he added.
For the study, total of 6 blood samples were collected from each of 56 healthy adult volunteers at Johns Hopkins Hospital. Samples were driven to a flight site an hour’s drive from the hospital on days when the temperature was moderate. There, half the samples were held stationary (non-flight); the other half were packaged for protection during the in-flight environment and to prevent leakage, then loaded into a hand-launched fixed-wing drone and flown for periods of 6–38 minutes. Owing to Federal Aviation Administration (FAA) rules, the flights were conducted in an unpopulated area, kept below 100 meters and in the line-of-sight of the certified drone pilot.
Samples were driven back from the flight-field to the Johns Hopkins Hospital Core Laboratory, where 33 of the most common chemistry, hematology, and coagulation tests were performed (tests that together account for around 80% of all such tests performed), including for sodium, glucose, and red blood cell count.
Comparing lab results of the flown vs. non-flown samples from each volunteer showed that these flights essentially had no impact, although the precision of one blood test—for total carbon dioxide (the bicarbonate test)—did differ for some samples pairs. This may be because the blood sat for up to 8 hours before being tested, but whether the out-of-range results were due to this time lag or to the drone transport is unknown. Nevertheless, there were no consistent differences in results between the flown vs. non-flown blood.
“The ideal way to test that would be to fly the blood around immediately after drawing it, but neither the FAA nor Johns Hopkins would like drones flying around the hospital,” said Dr. Amukele.
The likely next step is a pilot study in Africa where clinics are sometimes 60 or more miles away from labs. “A drone could go 100 km in 40 minutes,” said Dr. Amukele, “They’re less expensive than motorcycles, are not subject to traffic delays, and the technology already exists for the drone to be programmed to “home” to certain GPS coordinates, like a carrier pigeon.”
Drones have already been tested as carriers of medicines to clinics in remote areas, but whether and how drones will be used to carry medicines and potentially infectious patient specimens over more populated areas will depend on laws and regulations.
The study, by Amukele TK, et al, was published July 29, 2015, in the journal PLOS One.
Related Links:
Johns Hopkins University School of Medicine
Latest Hematology News
- Age-Specific CBC Reference Intervals Support Pediatric Diagnosis in Vietnam
- Spectral Flow Cytometry Assay Enhances MRD Detection in Multiple Myeloma
- New Marker Helps Detect Aggressive Multiple Myeloma Earlier
- New Biomarkers Predict Resistance to Targeted Therapy in Rare Blood Cancer
- AI Decision Support System Guides Treatment Selection for Complex Blood Cancers
- Blood Test Helps Predict Short-Term Mortality After Severe Heart Attack
- Next-Generation Hematology Platform Streamlines High-Complexity Lab Workflows
- Blood Eosinophil Count May Predict Cancer Immunotherapy Response and Toxicity
- Higher Ferritin Threshold May Improve Iron Deficiency Detection in Children
- Stem Cell Biomarkers May Guide Precision Treatment in Acute Myeloid Leukemia
- Advanced CBC-Derived Indices Integrated into Hematology Platforms
- Blood Test Enables Early Detection of Multiple Myeloma Relapse
- Single Assay Enables Rapid HLA and ABO Genotyping for Transplant Matching
- Prognostic Biomarker Identified in Diffuse Large B-Cell Lymphoma
- Routine Blood Test Parameters Link Anemia to Cancer Risk and Mortality
- Prognostic Tool Guides Personalized Treatment in Rare Blood Cancer
Channels
Clinical Chemistry
view channel
Machine Learning Model Shows Promise for Improving Metanephrine Testing Accuracy
Pheochromocytomas and paragangliomas are rare tumors that form in or near the adrenal glands and cause overproduction of stress hormones. Plasma-free metanephrines are the recommended first-line test,... Read more
Common HbA1c Assay May Miss Diabetes in People with Sickle Cell Trait
Accurate diabetes detection is essential because early identification guides timely management, yet test performance can vary in people with hemoglobin variants such as sickle cell trait.... Read moreMolecular Diagnostics
view channel
AI Tool Improves Long-Read Detection of Cancer Mutations
Accurate identification of somatic mutations remains difficult, particularly in structurally complex genomic regions. Short-read sequencing pipelines can miss clinically relevant variants, limiting research... Read more
FDA Clears Molecular Test for Bacterial Vaginosis and Candida Vaginitis
Vaginitis is a common reason for clinical visits, with bacterial vaginosis and Candida vaginitis among the leading causes. Overlapping symptoms and reliance on microscopy, pH testing, and clinical observation... Read moreHematology
view channel
Age-Specific CBC Reference Intervals Support Pediatric Diagnosis in Vietnam
Complete blood count (CBC) results underpin pediatric evaluation for anemia, infection, inflammation, and platelet disorders. Yet laboratories in Vietnam have largely relied on reference intervals derived... Read more
Spectral Flow Cytometry Assay Enhances MRD Detection in Multiple Myeloma
Minimal residual disease (MRD) monitoring is pivotal in multiple myeloma, where persistent malignant plasma cells drive relapse risk and help guide therapy decisions. In the United States, approximately... Read moreImmunology
view channel
Study Reveals Immune Mechanism Driving Severe COVID-19 Progression
Severe COVID-19 has highlighted gaps in understanding of early antiviral responses, particularly why some patients deteriorate despite timely care. Type I interferons are central to host defense, yet their... Read more
Antibody Profiling Identifies Preclinical Inflammatory Bowel Disease Years Before Diagnosis
Inflammatory bowel disease often develops after a prolonged symptom-free period, complicating timely recognition and clinical intervention. Limited understanding of immune activity during this silent phase... Read more
Ultrasensitive Blood Test Detects Sjögren’s Signature Years Before Diagnosis
Sjögren’s disease is a common autoimmune condition that can be difficult to recognize early, leading to delayed diagnosis and persistent symptom burden. It affects around half a million people in the UK... Read more
New Assays Expand Cytokine Testing for Transplant and Immunocompromised Patients
Eurofins Viracor has introduced three plasma-based assays—CXCL9 (Test Code 33607), CXCL10 (Test Code 33609), and interleukin-18 (IL-18) (Test Code 33611)—expanding its immunology testing menu for transplant... Read moreMicrobiology
view channel
New Sensitive Blood Assay Detects Tuberculosis Antigen Directly in Blood
Tuberculosis continues to be a leading global infectious disease, and diagnosis still hinges on sputum samples that many patients cannot produce early in illness. Delays in confirming Mycobacterium tuberculosis... Read more
High-Throughput Automated Platform to Advance Latent Tuberculosis Testing
Testing for tuberculosis remains a persistent global need, with demand driven by immigration screening, pre-treatment evaluation for immunosuppressive therapies, and public health programs.... Read morePathology
view channel
AI Pathology Tool Predicts Relapse Risk in Stage II Colorectal Cancer
Bowel cancer is Australia’s fourth most commonly diagnosed cancer and the second leading cause of cancer death, while remaining the third most common cancer worldwide. In stage-two disease, determining... Read more
AI Pathology Tool Stratifies Rectal Cancer to Guide Chemoradiotherapy
Choosing intensified regimens for locally advanced rectal cancer is challenging because these therapies can cause serious side effects. Colorectal cancer is the fourth-most fatal cancer in the UK, and... Read more
PD-L1 Assay Guides Pembrolizumab Eligibility in Ovarian, Fallopian Tube, and Peritoneal Cancers
Agilent Technologies’ PD-L1 IHC 22C3 pharmDx (Code SK006) has received European Union certification as a companion diagnostic to aid in identifying patients with epithelial ovarian, fallopian tube, or... Read moreIndustry
view channelLumiQuick Advances Oxidative Stress Research with Expanded AOXRE Portfolio
LumiQuick Diagnostics, Inc. (Santa Clara, CA, USA) has announced the addition of the AOXRE product line to its portfolio and introduced expanded services to help biotechnology and diagnostic companies... Read more
Collaboration Advances Sputum-Based Diagnostics for Asthma and COPD
Asthma and chronic obstructive pulmonary disease are highly prevalent inflammatory airway conditions, affecting more than 40 million Americans and more than 650 million people worldwide.... Read more








